Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 211 Lung Neoplasms 77 Triple Negative Breast Neoplasms 67 Breast Neoplasms 67 Ovarian Neoplasms 53 Squamous Cell Carcinoma of Head and Neck 49 Small Cell Lung Carcinoma 47 Fallopian Tube Neoplasms 34 Endometrial Neoplasms 34 Neoplasms 31 Parkinson Disease 4, Autosomal Dominant Lewy Body 28 Neoplasm Metastasis 28 Head and Neck Neoplasms 24 Prostatic Neoplasms 20 Esophageal Neoplasms 18 Carcinoma 18 Urinary Bladder Neoplasms 16 Colorectal Neoplasms 16 Uterine Cervical Neoplasms 14 Oropharyngeal Neoplasms 14 Carcinoma, Transitional Cell 14 Carcinoma, Squamous Cell 14 Esophageal Squamous Cell Carcinoma 12 Brain Neoplasms 12 Stomach Neoplasms 10 Pancreatic Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 10 Mouth Neoplasms 9 Laryngeal Neoplasms 9 Advanced Solid Tumors 9

Interventions

pembrolizumab 2 poly(I).poly(c12,U) 1 liposomal doxorubicin 1 Platinum Compounds 1 Paclitaxel 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Carboplatin × 1 year × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡